FCF Healthcare & Life Sciences Venture Capital Monitor — Europe — Published in July 2026

The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly overview of financing trends in the venture capital sector, with a focus on European healthcare and life sciences companies.

As of the end of July 2026, we have identified the following current VC trends in Europe:

• Total Healthcare & Life Sciences funding reached EUR 7,236m (+4% vs. 2025)

• Biotech/Pharma received 33% of the total investment volume (EUR 2,397m), with oncology being the leading indication (35%)

• In July, Neko Health (Sweden) secured the highest transaction volume with EUR 612m, followed by Draig Therapeutics (United Kingdom) with EUR 76m and Xeltis (Netherlands) with EUR 71m

• GV (United States) is the most active investor (by deal volume in 2026), followed by Alphabet (United States) and CapitalG (United States)